The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 23, 2026 for Aayush Agrawal, ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Midcap 150 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aayush Agrawal, trustee of Aayush Agrawal Trust and promoter of Ajanta Pharma, reported to the exchanges that he created a pledge on 2,00,000 shares (0.16% of total share capital) on 19 February 2026 in favour of Aditya Birla Capital Ltd to raise additional borrowing. Earlier, on 17 February 2026, he had released a pledge on 2,00,000 shares (0.16%) from the same lender on account of loan repayment. After these two events, the trust's encumbered (pledged) holding stands at 80,48,407 shares, which is 6.44% of the company's share capital, against its total holding of 1,41,12,924 shares (11.30%). The pledge creation and release are of equal size, so there is no net change in the overall pledged position.
This is a routine refinancing activity by a single promoter trust – one pledge was closed (loan repaid) while a fresh one of identical size was opened to draw a new loan. There is no change in the promoter's stake or in the total pledged percentage, so it is unlikely to have a meaningful impact on the stock price or shareholder concerns.